Author

J. A. Simpson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Physiology· 3 Biophysics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 4 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:metabolism & bioenergetics· 2

Frequent Co-Authors

M. C. Garibotti· 3 shared J. McCaw· 2 shared J. Petrik· 2 shared J. S. McCarthy· 2 shared K. Matuszewska· 2 shared K. R. Brunt· 2 shared L. J. Delfinis· 2 shared L. M. Ogilvie· 2 shared

Activity by Year

2017-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPhysiology

M. C. Garibotti

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Yap is a Nutrient Sensor Sensitive to the Amino Acid L-Isoleucine and Regulates Expression of Ctgf in Cardiomyocytes.

V. L. Nelson, A. L. Eadie, M. Madhu, M. J. Platt, T. PULINILKUNNIL, P. Kienesberger, J. A. Simpson, K. R. Brunt

The paper shows Yap signaling in cardiomyocytes is sensitive to L-isoleucine and regulates Ctgf expression, influencing myocardial adaptation after injury.

bioRxiv · Apr 25, 2024Pharmacology & Toxicology

Muscle weakness and mitochondrial stress occur before metastasis in a novel mouse model of ovarian cancer cachexia

L. J. Delfinis, L. M. Ogilvie, S. Khajehzadehshoushtar, S. Gandhi, M. C. Garibotti, A. K. Thuhan, K. Matuszewska, M. Pereira, R. G. Jones, A. J. Cheng, T. J. Hawke, N. P. Greene, K. Murach, J. A. Simpson, J. Petrik, C. Perry

This paper introduces a novel mouse model of ovarian cancer cachexia showing that muscle weakness and mitochondrial stress occur before metastasis and atrophy in specific muscles.

bioRxiv · Apr 8, 2024 · PreprintPhysiology

Disrupted cardiac bioenergetics linked to oxidized mitochondrial creatine kinase are rescued by the mitochondrial-targeting peptide SBT-20 in the D2.mdx model of Duchenne muscular dystrophy

C. G. R. Perry, M. C. Hughes, S. V. Ramos, A. Brahmbhatt, P. C. Turnbull, N. Polidovitch, M. C. Garibotti, U. Schlattner, T. J. Hawke, J. A. Simpson, P. H. Backx

This paper investigates how mitochondrial bioenergetics are affected in D2.mdx mice and shows that SBT-20 can improve creatine-dependent bioenergetics by reducing oxidative stress.

bioRxiv · Feb 4, 2024 · PreprintPhysiology

Cardiac atrophy, dysfunction, and metabolic impairments: a cancer-induced heart failure phenotype

L. M. Ogilvie, L. J. Delfinis, B. Coyle-Asbil, V. Vudatha, R. Alshamali, B. Garlisi, M. Pereira, K. Matuszewska, M. C. Garibotti, S. Gandhi, K. R. Brunt, J. G. Trevino, C. G. Perry, J. Petrik, J. A. Simpson

This study shows that cancer causes cardiac atrophy, dysfunction, and metabolic changes similar to heart failure in mouse models.

bioRxiv · Sep 30, 2023 · PreprintPhysiology

Characterisation of Plasmodium vivax lactate dehydrogenase dynamics in P. vivax infections

P. Cao, S. Kho, M. J. Grigg, B. E. Barber, K. A. Piera, T. William, J. R. Poespoprodjo, I. K. Jang, J. A. Simpson, J. McCaw, N. M. Anstey, J. S. McCarthy, S. Britton

This study models PvLDH dynamics in P. vivax infections using Bayesian inference, finding significant differences between ex vivo and in vivo PvLDH levels and half-lives.

bioRxiv · Jun 12, 2023 · PreprintBiophysics

Seeking an optimal dosing regimen for OZ439-DSM265 combination therapy for treating uncomplicated falciparum malaria

S. Dini, S. G. Zaloumis, D. J. Price, N. Gobeau, A. Kuemmel, M. Cherkaoui, J. J. Moehrle, J. S. McCarthy, J. A. Simpson

This study uses a mathematical model to determine an optimal dosing regimen for OZ439-DSM265 combination therapy to treat uncomplicated falciparum malaria, predicting a regimen that cures 90% of patients within 42 days.

bioRxiv · Nov 2, 2020Pharmacology & Toxicology

Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating Plasmodium falciparum malaria patients using mathematical modelling

J. A. Simpson, J. McCaw, P. Cao, F. J.I. Fowkes, S. Zaloumis, R. N. Price, S. Dini

This paper uses mathematical modeling to evaluate the efficacy of triple artemisinin-based combination therapy (TACT) against Plasmodium falciparum malaria, showing that adding mefloquine improves parasitological outcomes despite drug resistance.

bioRxiv · May 27, 2018Pharmacology & Toxicology

Cellular Interplay and Cytokine Hierarchy Cause Pathological Cardiac Hypertrophy in RAF1-Mutant Noonan Syndrome

J. C. Yin, M. J. Platt, X. Tian, X. Wu, P. H. Backx, J. A. Simpson, T. Araki, B. G. Neel

This study shows that RAF1 mutations in Noonan syndrome cause cardiac hypertrophy through cytokine signaling from endothelial cells, with TNF/IL6 as potential therapeutic targets.

bioRxiv · Mar 30, 2017Cell Biology